Scharnagl H - Search Results

1

Associations of functional alanine-glyoxylate aminotransferase 2 gene variants with atrial fibrillation and ischemic stroke.

Seppälä I, Kleber ME, Bevan S, Lyytikäinen LP, Oksala N, Hernesniemi JA, Mäkelä KM, Rothwell PM, Sudlow C, Dichgans M, Mononen N, Vlachopoulou E, Sinisalo J, Delgado GE, Laaksonen R, Koskinen T, Scharnagl H, Kähönen M, Markus HS, März W, Lehtimäki T. Seppälä I, et al. Among authors: scharnagl h. Sci Rep. 2016 Mar 17;6:23207. doi: 10.1038/srep23207. Sci Rep. 2016. PMID: 26984639 Free PMC article.

2

Decreased binding of apolipoprotein (a) to familial defective apolipoprotein B-100 (Arg3500-->Gln). A study of the assembly of recombinant apolipoprotein (a) with mutant low density lipoproteins.

Durovic S, März W, Frank S, Scharnagl H, Baumstark MW, Zechner R, Kostner GM. Durovic S, et al. Among authors: scharnagl h. J Biol Chem. 1994 Dec 2;269(48):30320-5. J Biol Chem. 1994. PMID: 7982944 Free article.

3

Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol.

Scharnagl H, Kist M, Grawitz AB, Koenig W, Wieland H, März W. Scharnagl H, et al. Am J Cardiol. 2004 Jan 15;93(2):219-20. doi: 10.1016/j.amjcard.2003.09.045. Am J Cardiol. 2004. PMID: 14715353 Clinical Trial.

4

Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism.

Scharnagl H, Petersen G, Nauck M, Teichmann AT, Wieland H, März W. Scharnagl H, et al. Contraception. 2004 Feb;69(2):105-13. doi: 10.1016/j.contraception.2003.10.004. Contraception. 2004. PMID: 14759614 Clinical Trial.

5

Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study.

März W, Scharnagl H, Winkler K, Tiran A, Nauck M, Boehm BO, Winkelmann BR. März W, et al. Among authors: scharnagl h. Circulation. 2004 Nov 9;110(19):3068-74. doi: 10.1161/01.CIR.0000146898.06923.80. Epub 2004 Oct 25. Circulation. 2004. PMID: 15505088

6

The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study).

März W, Scharnagl H, Hoffmann MM, Boehm BO, Winkelmann BR. März W, et al. Among authors: scharnagl h. Eur Heart J. 2004 Dec;25(23):2109-19. doi: 10.1016/j.ehj.2004.08.024. Eur Heart J. 2004. PMID: 15571826

7

Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study.

Renner W, Nauck M, Winkelmann BR, Hoffmann MM, Scharnagl H, Mayer V, Boehm BO, März W; LURIC Study team. Renner W, et al. Among authors: scharnagl h. J Mol Med (Berl). 2005 Mar;83(3):235-9. doi: 10.1007/s00109-004-0618-0. Epub 2004 Dec 15. J Mol Med (Berl). 2005. PMID: 15599691

8

ApoE: crossroads between Alzheimer's disease and atherosclerosis.

Stojakovic T, Scharnagl H, März W. Stojakovic T, et al. Among authors: scharnagl h. Semin Vasc Med. 2004 Aug;4(3):279-85. doi: 10.1055/s-2004-861496. Semin Vasc Med. 2004. PMID: 15630629 Review.

9

New lipid-lowering agents acting on LDL receptors.

Scharnagl H, März W. Scharnagl H, et al. Curr Top Med Chem. 2005;5(3):233-42. doi: 10.2174/1568026053544524. Curr Top Med Chem. 2005. PMID: 15857307 Review.

10

Lifibrol: first member of a new class of lipid-lowering drugs?

Scharnagl H, März W, Wieland H. Scharnagl H, et al. Expert Opin Investig Drugs. 1997 May;6(5):583-91. doi: 10.1517/13543784.6.5.583. Expert Opin Investig Drugs. 1997. PMID: 15989622

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

291 results

Search Page